UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

GM1-Ganglioside Accumulation at the Mitochondria-Associated ER Membranes Links ER Stress to Ca2+-Dependent Mitochondrial Apoptosis

Molecular cell, 2009-11, Vol.36 (3), p.500-511

2009

Volltextzugriff (PDF)

Altered GM1 catabolism affects NMDAR-mediated Ca2+ signaling at ER-PM junctions and increases synaptic spine formation in a GM1-gangliosidosis model

Cell reports (Cambridge), 2024-05, Vol.43 (5), p.114117, Article 114117

2024

Volltextzugriff (PDF)

Alix-mediated assembly of the actomyosin–tight junction polarity complex preserves epithelial polarity and epithelial barrier

Nature communications, 2016-06, Vol.7 (1), p.11876-11876, Article 11876

2016

Volltextzugriff (PDF)

Regulated lysosomal exocytosis mediates cancer progression

Science advances, 2015-12, Vol.1 (11), p.e1500603-e1500603

2015

Volltextzugriff (PDF)

Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis

Science advances, 2019-07, Vol.5 (7), p.eaav3270-eaav3270

2019

Volltextzugriff (PDF)

AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study

Molecular therapy. Methods & clinical development, 2021-12, Vol.23, p.644-658

2021

Volltextzugriff (PDF)

Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis

Cells (Basel, Switzerland), 2022-08, Vol.11 (16), p.2579

2022

Volltextzugriff (PDF)

Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept

Molecular therapy. Methods & clinical development, 2021-03, Vol.20, p.191-203

2021

Volltextzugriff (PDF)

Muscle degeneration in neuraminidase 1-deficient mice results from infiltration of the muscle fibers by expanded connective tissue

Biochimica et biophysica acta, 2010-07, Vol.1802 (7), p.659-672

2010

Volltextzugriff (PDF)

GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis

Molecular cell, 2009-11, Vol.36 (3), p.500-511

2009

Volltextzugriff (PDF)

Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-β secretion via deregulated lysosomal exocytosis

Nature communications, 2013-11, Vol.4 (1), p.2734-2734, Article 2734

2013

Volltextzugriff (PDF)

AAV-mediated gene therapy in a mouse model of sialidosis

Molecular genetics and metabolism, 2023-02, Vol.138 (2), p.107342, Article 107342

2023

Volltextzugriff (PDF)

AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study

Molecular genetics and metabolism, 2023-02, Vol.138 (2), p.107105, Article 107105

2023

Volltextzugriff (PDF)

AAV-mediated gene therapy for sialidosis

Molecular therapy, 2024-07, Vol.32 (7), p.2094-2112

2024

Volltextzugriff (PDF)

Distinct functions of dimeric and monomeric scaffold protein Alix in regulating F-actin assembly and loading of exosomal cargo

The Journal of biological chemistry, 2022-10, Vol.298 (10), p.102425-102425, Article 102425

2022

Volltextzugriff (PDF)

Preclinical enzyme replacement therapy with a recombinant β-galactosidase-lectin fusion for CNS delivery and treatment of GM1-gangliosidosis

Molecular genetics and metabolism, 2023-02, Vol.138 (2), p.107356, Article 107356

2023

Volltextzugriff (PDF)

Chaperone mediated gene therapy for type I sialidosis

Molecular genetics and metabolism, 2016-02, Vol.117 (2), p.S21-S21

2016

Volltextzugriff (PDF)

Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis

Biochimica et biophysica acta, 2013-10, Vol.1832 (10), p.1784-1792

2013

Volltextzugriff (PDF)

Altered GM1 catabolism affects NMDAR-mediated Ca 2+ signaling at ER-PM junctions and increases synaptic spine formation in a GM1-gangliosidosis model

Cell reports (Cambridge), 2024-05, Vol.43 (5), p.114117

2024

Volltextzugriff (PDF)

Preclinical Dose-Finding Study With a Liver-Tropic, Recombinant AAV-2/8 Vector in the Mouse Model of Galactosialidosis

Molecular therapy, 2012-02, Vol.20 (2), p.267-274

2012

Volltextzugriff (PDF)

Preclinical study of a scAAV2/8-Lp1-huPPCA vector in the treatment of the galactosialidosis mouse model

Molecular therapy, 2013-09, Vol.21 (9), p.e15-e15

2013

Volltextzugriff (PDF)

GM1-Ganglioside Accumulation at the Mitochondria-Associated ER Membranes Links ER Stress to Ca[super]2+-Dependent Mitochondrial Apoptosis

Molecular cell, 2009-11, Vol.36 (3), p.500-511

2009

Volltextzugriff (PDF)

Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-[beta] secretion via deregulated lysosomal exocytosis

Nature communications, 2013-11, Vol.4, p.2734

2013

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

GM1-Ganglioside Accumulation at the Mitochondria-Associated ER Membranes Links ER Stress to Ca2+-Dependent Mitochondrial Apoptosis

Altered GM1 catabolism affects NMDAR-mediated Ca2+ signaling at ER-PM junctions and increases synaptic spine formation in a GM1-gangliosidosis model

Alix-mediated assembly of the actomyosin–tight junction polarity complex preserves epithelial polarity and epithelial barrier

Regulated lysosomal exocytosis mediates cancer progression

Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis

AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study

Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis

Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept

Muscle degeneration in neuraminidase 1-deficient mice results from infiltration of the muscle fibers by expanded connective tissue

GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis

Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-β secretion via deregulated lysosomal exocytosis

AAV-mediated gene therapy in a mouse model of sialidosis

AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study

AAV-mediated gene therapy for sialidosis

Distinct functions of dimeric and monomeric scaffold protein Alix in regulating F-actin assembly and loading of exosomal cargo

Preclinical enzyme replacement therapy with a recombinant β-galactosidase-lectin fusion for CNS delivery and treatment of GM1-gangliosidosis

Chaperone mediated gene therapy for type I sialidosis

Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis

Altered GM1 catabolism affects NMDAR-mediated Ca 2+ signaling at ER-PM junctions and increases synaptic spine formation in a GM1-gangliosidosis model

Preclinical Dose-Finding Study With a Liver-Tropic, Recombinant AAV-2/8 Vector in the Mouse Model of Galactosialidosis

Preclinical study of a scAAV2/8-Lp1-huPPCA vector in the treatment of the galactosialidosis mouse model

GM1-Ganglioside Accumulation at the Mitochondria-Associated ER Membranes Links ER Stress to Ca[super]2+-Dependent Mitochondrial Apoptosis

Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-[beta] secretion via deregulated lysosomal exocytosis

Suchergebnisse filtern